Schultze-Seemann W
Urologische Abteilung, Universität Freiburg.
Fortschr Med. 1993 Sep 10;111(25):394-7.
The incidence of benign prostatic hyperplasia of up to 80% in 80-year-old men raises question as to possible therapeutic consequences. For decades, the standard treatment has consisted in transurethral resection of the prostate (TUR-P) which results in subjective and objective improvement in up to 95% of the cases and has low morbidity and negligible mortality. With a view to establishing a minimally invasive form of treatment, the search for alternative therapies makes good sense. To date, however, various medical therapeutic approaches (phytotherapy, alpha-blockers, antiandrogens, 5-alpha-reductase inhibitors) and/or interventional measures (thermotherapy, stents, balloon dilatation) have failed to match the therapeutic efficacy of TUR. However, in individuals at a high risk of surgery, they represent practicable alternatives.
80岁男性良性前列腺增生的发病率高达80%，这引发了对可能的治疗后果的质疑。几十年来，标准治疗方法一直是经尿道前列腺切除术（TUR-P），该方法在高达95%的病例中能带来主观和客观上的改善，且发病率低、死亡率可忽略不计。为了建立一种微创治疗方式，寻找替代疗法是很有意义的。然而，迄今为止，各种医学治疗方法（植物疗法、α受体阻滞剂、抗雄激素药物、5α还原酶抑制剂）和/或介入措施（热疗、支架、球囊扩张）都未能达到TUR的治疗效果。不过，对于手术风险高的患者，它们是可行的替代方案。
